Diabetes and CoViD-19: Experience from the frontline of Internal Medicine wards in Italy.
Betacoronavirus
COVID-19
Comorbidity
Coronavirus Infections
/ epidemiology
Diabetes Mellitus
/ epidemiology
Diabetes Mellitus, Type 2
/ epidemiology
Hospitals
Humans
Incidence
Internal Medicine
Italy
/ epidemiology
Pandemics
Pneumonia, Viral
/ epidemiology
Prognosis
SARS-CoV-2
Surveys and Questionnaires
CoViD-19
Mortality
Type 2 diabetes
Journal
Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
14
07
2020
accepted:
14
07
2020
pubmed:
21
7
2020
medline:
6
10
2020
entrez:
21
7
2020
Statut:
ppublish
Résumé
Available data suggest that the issue of CoViD-19 is particularly critical in patients with diabetes. In Italy, Internal Medicine (IM) wards have played a pivotal role in contrasting the spread of SARS-Cov2. During this pandemic, FADOI submitted a brief questionnaire to a group of its members acting as Head of IM units. Considering 38 units, 58% of beds dedicated to CoViD patients in CoViD Hospitals were in charge of IM, and globally cared for 6650 patients during a six-week period. Of these patients, 1264 (19%) had diabetes. Mortality rate in CoViD patients with or without diabetes were 20.5% and 14%, respectively (p < 0.001). Our survey seems to confirm that diabetes is a major comorbidity of CoViD-19, but it does not support an increased incidence of CoViD-19 infection in people with diabetes, if compared with the figures of patients with diabetes and hospitalized before the outbreak. On the other side, patients with diabetes appeared at a significantly increased risk of worse outcome. This finding underlines the importance of paying special attention to this patient population and its management.
Identifiants
pubmed: 32687955
pii: S0168-8227(20)30587-8
doi: 10.1016/j.diabres.2020.108335
pmc: PMC7367793
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108335Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Lancet Diabetes Endocrinol. 2020 Jun;8(6):546-550
pubmed: 32334646
J Infect Public Health. 2020 May;13(5):667-673
pubmed: 32340833
Diabetes Res Clin Pract. 2020 May;163:108186
pubmed: 32360400
Acta Diabetol. 2014 Oct;51(5):765-70
pubmed: 24722913
Diabetes Care. 2020 Jul;43(7):1408-1415
pubmed: 32430456
Eur J Intern Med. 2020 Jul;77:143
pubmed: 32381324
Diabetes Res Clin Pract. 2020 May;163:108151
pubmed: 32305399
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
Int J Infect Dis. 2020 Mar;92:208-213
pubmed: 31978583
Diabetes Care. 2020 Jul;43(7):1427-1432
pubmed: 32409501
Mol Cell Endocrinol. 2009 Apr 29;302(2):193-202
pubmed: 18948167
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Diabetes Res Clin Pract. 2020 Apr;162:108125
pubmed: 32224164
Diabetes Obes Metab. 2020 Oct;22(10):1951-1952
pubmed: 32463166